Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab monotherapy in resectable squamous cell lung cancer
NCT05784974Phase 2Not yet recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- May 2023
- Primary completion
- May 2025
- Modality
- Bispecific Antibodies
01
Overview
A Phase 2 trial of cadonilimab in squamous cell carcinoma of the lung (LSCC), sponsored by The First Hospital of Jilin University. Planned start May 2023; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
squamous cell carcinoma of the lung (LSCC)
Beyond the preview
Go deeper on NCT05784974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05784974.